Joshua Pinto is CFO at Neumora Therapeutics, Inc. (NMRA). They have made 1 open-market trade across 1 company since 2024, most recently 2026-02-17.
CIK 0001992595
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 1 sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| NMRA | 57,783 | $28K |
Shares reported on the most recent Form 4, priced at the 2026-02-19 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| NMRA | SELL | 2026-02-17 | 2026-02-19 | $3.54 | $21K | -12.1% | -29.0% | -50.3% |
| NMRA | SELL · 10b5-1 | 2025-02-18 | 2025-02-20 | $1.67 | $13K | -18.0% | -30.2% | -56.1% |
| NMRA | SELL · 10b5-1 | 2024-08-27 | 2024-08-27 | $11.39 | $357K | -1.5% | +13.0% | -16.5% |
| NMRA | SELL · 10b5-1 | 2024-08-22 | 2024-08-26 | $11.67 | $2.0M | -8.9% | +11.5% | -15.8% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.